A retrospective study including six ALK‐positive NSCLC patients found ALK rearrangement to be associated with low overall response rates to PD‐1/PD‐L1 blockade.22 Most recently, in the Supplementary data of a large scale phase 2 study (ATLANTIC) that included 15 ALK‐positive NSCLC patients treated with durvalumab as third‐line or later therapy, ALK‐positive NSCLC patients had a tendency of poor OS and PFS compared to EGFR‐positive patients.23 These findings are consistent with our study. Here, ALK is linked to non-small cell lung carcinoma.